TCAV-CT: Effects of TCAV and Volume Control Ventilation on the Distribution of Aerated Lung Parenchyma in ARDS Patients

Sponsor
Central Hospital, Nancy, France (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05874973
Collaborator
(none)
33
1
2
16.2
2

Study Details

Study Description

Brief Summary

Acute respiratory distress syndrome (ARDS) is a severe form of acute respiratory failure with mortality rates reaching as high as 35%. Management of ARDS is based on the treatment (if possible) of the underlying cause of ARDS and on invasive mechanical ventilation with positive expiratory pressure (PEEP). Another strategy of invasive ventilation, Time-Controlled Adaptative Ventilation (TCAV), is the application of specific settings to the airway pressure release ventilation (APRV) mode.

TCAV is based on a prolonged time at plateau pressure, creating a phase of continuous positive pressure, associated with brief release phases allowing the elimination of carbon dioxide. In prospective and retrospective clinical reviews, as well as in experimental animal studies, TCAV has demonstrated improvements in oxygenation and lung function, with the ability to prevent ARDS.

The thoracic computed tomography (CT) scan evaluates lung recruitment (re-aeration by positive pressure of non-ventilated lung territories) and the adverse effects of positive pressure on the parenchyma (hyperinflation).

The objective of this study is to evaluate, with CT scans performed to assess lungs of patients with ARDS, the effects of TCAV compared to a standard volumetric controlled ventilation, by measuring alveolar recruitment and over-distension.

Condition or Disease Intervention/Treatment Phase
  • Other: Time-controlled adaptative ventilation (TCAV)
  • Other: Volume-controlled ventilation (VCV)
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
33 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effects of Time-controlled Adaptive Ventilation (TCAV) and Volume Control Ventilation (VCV) on the Distribution of Aerated Lung Parenchyma in Patients With Acute Respiratory Distress Syndrome (ARDS): a Pilot Study
Anticipated Study Start Date :
May 25, 2023
Anticipated Primary Completion Date :
Mar 31, 2024
Anticipated Study Completion Date :
Sep 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Time-Controlled Adaptative Ventilation (TCAV)

APRV mode set with: a Phigh at Plateau Pressure of the VCV mode a Tlow set to terminate the expiration at 75% of the maximal expiratory flow a Plow set at 0 cmH2O. a Thigh set to achieve adequate decarboxylation.

Other: Time-controlled adaptative ventilation (TCAV)
Ventilation with TCAV set on the APRV mode on the ventilator.

Active Comparator: Volume Control Ventilation (VCV)

Ventilation with the VCV mode set with: a tidal volume (VT) at or below 6 ml/kg of predicted body weight a positive end-expiratory pressure (PEEP) set at least at 5 cmH2O a driving pressure lower than 15 cmH2O.

Other: Volume-controlled ventilation (VCV)
Ventilation with the VCV mode set on the ventilator.

Outcome Measures

Primary Outcome Measures

  1. Percentage of end-expiratory non aerated lung parenchyma [10 minutes]

    Percentage of non aerated lung parenchyma defined as % of lung at -100 to +100 Hounsfield Units (HU) divided by total lung weight, at the end of expiration.

Secondary Outcome Measures

  1. End-inspiratory overdistention in TCAV [10 minutes]

    Percentage of hyper-aerated lung parenchyma defined as lung volume at ≤ - 901 Hounsfield Units (HU) divided by total lung volume, at the end of inspiration in TCAV.

  2. Tidal hyperinflation in TCAV [10 minutes]

    Tidal hyperinflation is defined as the volume of the hyper-aerated (density ≤ - 901 HU) compartment at end-inspiration minus hyper-aerated (density ≤ - 901 HU) volume at end-expiration, and standardized to predicted body weight (PBW), expressed in ml/kg of PBW

  3. Atelectrauma in TCAV and VCV [10 minutes]

    Tidal recruitment of the non-aerated (-100 to +100 Hounsfield Units) compartment was defined as the weight of the non-aerated compartment at end-expiration minus its weight at end-inspiration, and standardized to total lung weight, expressed in %.

  4. Correlation between transpulmonary driving pressure and tidal hyperinflation in TCAV [10 minutes]

    Area under ROC curve of transpulmonary driving pressure to detect cyclic hyperinflation

  5. Correlation between driving pressure and tidal hyperinflation in TCAV [10 minutes]

    Area under ROC curve of driving pressure to detect cyclic hyperinflation

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • ARDS according to the Berlin definition

  • invasive ventilation for no longer than 72 hours

  • patient requiring a diagnostic thoracic CT scan

  • consent of a family member or the person of trust

  • social security affiliation

Exclusion Criteria:
  • Use of iodinated contrast media injection before CT acquisitions

  • ARDS criteria present during 72 hours or more

  • Severe COPD

  • Pneumothorax or other barotrauma-related complication

  • Right ventricular failure other than acute cor pulmonale

  • Absence of sedative agents and neuromuscular blockade

  • Severe hemodynamic instability (norepinephrine > 0.5 µg/kg/min)

  • VA-ECMO assistance

  • Pregnancy

  • Absence of the capacity to give consent before admission to the ICU

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHRU Nancy France

Sponsors and Collaborators

  • Central Hospital, Nancy, France

Investigators

  • Principal Investigator: Benjamin Pequignot, CHRU Nancy

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
PEQUIGNOT Benjamin, Dr, Central Hospital, Nancy, France
ClinicalTrials.gov Identifier:
NCT05874973
Other Study ID Numbers:
  • 2021PI212
First Posted:
May 25, 2023
Last Update Posted:
May 25, 2023
Last Verified:
May 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by PEQUIGNOT Benjamin, Dr, Central Hospital, Nancy, France

Study Results

No Results Posted as of May 25, 2023